# Bioeast Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioeast-biotech

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.bioeast.com
- Total disclosed funding: $40M
- Latest round: Series A (May 9, 2022)
- Investors on record: 5

## About

Based in Hangzhou, China and established in 2018, Bioeast Biotech is a pharmaceutical raw material supplier dedicated to providing IVD core raw materials and overall solutions. In has a subsidiary in Hangzhou. The company acquired ISO 13485 Quality Management System Certification. In July 2023, it was awarded the title of National Specialized and New Small Giant Enterprise. In June 2024, the company closed strategic investment from new investors Heda Venture and ZJVC Venture Capital.

The company mainly provides core raw materials and overall solutions. It provides core raw materials such as antigens, antibodies, enzymes, quality control products, nano-microspheres, etc. Bioeast also provides nanometre microspheres, immunodiagnostics, purification media, and molecular products. The immunodiagnostics include antigens and antibodies, enzymes and proteins, and pet diagnosis. The molecular products include nucleic acid purification series, PCR (Polymerase Chain Reaction) series, qPCR (Quantitative PCR) series, and reverse transcription series. The company also provides IVD companies with comprehensive solutions for POCT (Point-of-Care Testing), immunoturbidimetry, chemiluminescence and other products.

The company generates revenue by providing core raw materials and overall solutions such as nanometre microspheres, immunodiagnostics, purification media, and molecular products.

## Funding rounds

- Series A, May 9, 2022, $23M — LYFE Capital
- Series A, Sep 3, 2021, $16M — China Growth Capital, YuanBio Venture, Co-Win Ventures, Grand Mount Capital
- Angel, Nov 25, 2020, $1.5M — YuanBio Venture, Co-Win Ventures

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel, Series A
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Angel, Series A
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series A
- Grand Mount Capital (https://capitalatlas.ai/funds/grand-mount-capital) — Series A
- LYFE Capital — Series A